BTK and B-cell chronic lymphocytic leukemia: Zanubrutinib (BRUKINSATM, Beigene Corporation; also known as BGB-3111) is an irreversible next-generation BTK inhibitor that was approved for the treatment of recurrent or refractory CLL, MCL, and WM (20–22).